According to Zhitong Financial App, Blue Biotech (603739.SH) disclosed the 2023 semi-annual report. During the reporting period, the company achieved revenue of 544 million yuan, an increase of 2.13%; net profit of 31.47 million yuan, a year-on-year decrease of 15.87%; net profit of 17.27 million yuan, a year-on-year decrease of 28.65%; and basic earnings per share of 0.12 yuan.
In the first half of 2023, 32 domestic authorized invention patents were added, and 3 PCT international applications were filed. By the end of the reporting period, the company and its subsidiaries had 367 domestic authorized invention patents, 8 US authorized patents, 2 European authorized patents, 27 PCT international applications, and 39 new veterinary drug registration certificates (including 3 new national first-class veterinary drugs).